Clinical trials: Ophthalmic Solutions
Open-angle Glaucoma, Ocular Hypertension
Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.
- Trial name
- SEE-1 (NCT02179008)
- Testing
- DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- Santen Inc.
Glaucoma, Open Angle, Ocular Hypertension
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate.
- Trial name
- NCT00804648
- Testing
- Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vistakon Pharmaceuticals
Myopia, Astigmatism
Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Soft Contact Lens Wearers
The purpose of this study is demonstrate substantial equivalence of an investigational contact lens disinfecting solution to a commercially available contact lens solution in silicone hydrogel and soft contact lens wearers.
- Conditions
- Myopia, Astigmatism, Hyperopia, Refractive Error
- Trial name
- NCT01912768
- Testing
- FID 120947A contact lens disinfecting solution, renu fresh multi-purpose solution, Soft contact lenses
- Volunteers
- 362 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the intraocular pressure (IOP)-lowering effect and safety of DE-104 ophthalmic solution in patients with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00656240
- Testing
- DE-104 ophthalmic solution, DE-104 vehicle
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma
Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
- Trial name
- PRO-179/I (NCT03965052)
- Testing
- PRO 179, Travatan 0.004 % Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Macular Edema
Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema
To evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution, EGP-437, using the EyeGate® II Drug Delivery System (EGDS) in patients with macular edema (ME)
- Trial name
- NCT02485249
- Testing
- Dexamethasone Phosphate Ophthalmic
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Bacterial Conjunctivitis
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.
- Trial name
- NCT01573910
- Testing
- Moxifloxacin ophthalmic solution, 0.5%, Ofloxacin ophthalmic solution, 0.3%
- Where
- China
- Volunteers
- 985 people
- Sponsor
- Alcon Research
Non-infectious Anterior Uveitis
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis.
- Trial name
- NCT02406209
- Testing
- NS2, Prednisolone acetate ophthalmic suspension (1%)
- Where
- 15 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Glaucoma and Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
The purpose of this study is to investigate the safety and efficacy of up to three concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as monotherapy and as adjunctive therapy (DE-117 ophthalmic…
- Trial name
- NCT01654484
- Testing
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Ocular Hypertension, Open Angle Glaucoma
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
- Trial name
- NCT02874846
- Testing
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye Disease
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734197
- Testing
- SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%
- Where
- 40 sites in United States
- Volunteers
- 349 people
- Sponsor
- Surface Ophthalmics, Inc.
Bacterial Conjunctivitis
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
A randomized, double blind, phase II multicenter trial with the objective of assess the safety and efficacy of the PRO-157 ophthalmic solution in three different dosing regimens, versus Moxifloxacin, versus Gatifloxacin in…
- Trial name
- Pazufloxacin (NCT02980523)
- Testing
- PRO-157, Vigamox, Zymar®
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease (DED)
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.
- Trial name
- NCT06879782
- Where
- China
- Volunteers
- 820 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Corneal Epithelial Disorders
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02929823
- Testing
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Where
- 19 sites in United States
- Volunteers
- 130 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Allergic Conjunctivitis of Both Eyes
Daydrop® Triple Action for Allergic Eye Symptoms
The study is designed to evaluate the safety and efficacy of Daydrop® Triple Action for the symptomatic treatment of seasonal or perennial allergic conjunctivitis.
- Trial name
- NCT07805759
- Testing
- Eye Drops, Lubricant
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- i+Med S.Coop.
Healthy
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of CTO0101
- Trial name
- NCT05262179
- Testing
- CTO0101
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Macular Degeneration, Age-related Macular Degeneration
A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.
- Trial name
- NCT00463320
- Testing
- Pazopanib eye drops and Allergen Refresh Plus eye drops
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dry Eye Syndromes
A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease
The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.
- Trial name
- NCT01135511
- Testing
- CP-690,550 Eye drops, CP-690,550 Eye drops-vehicle, Sodium Hyaluronate
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 285 people
- Sponsor
- Pfizer
Dry Eye Disease (DED)
Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease
The goal of this prospective, open, monocentric study is to evaluate the clinical efficacy of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA in 30 patients with chronic dry eye disease and…
- Trial name
- NCT07007702
- Testing
- T2769
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Laboratoires Thea
Allergic Conjunctivitis
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis using a modified Conjunctival Allergen Challenge…
- Trial name
- NCT03368339
- Testing
- PR013 (0.045%), PR013 (0.06%), Vehicle
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Realm Therapeutics, Inc.